Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Camanni F., Massara F., Belforte L., Molinatti G. M. Changes in plasma growth hormone levels in normal and acromegalic subjects following administration of 2-bromo-alpha-ergocryptine. J Clin Endocrinol Metab. 1975 Mar;40(3):363–366. doi: 10.1210/jcem-40-3-363. [DOI] [PubMed] [Google Scholar]
- Cools A. R., Van Rossum J. M. Excitation-mediating and inhibition-mediating dopamine-receptors: a new concept towards a better understanding of electrophysiological, biochemical, pharmacological, functional and clinical data. Psychopharmacologia. 1976 Feb 2;45(3):243–254. doi: 10.1007/BF00421135. [DOI] [PubMed] [Google Scholar]
- Cotzias G. C., Papavasiliou P. S., Tolosa E. S., Mendez J. S., Bell-Midura M. Treatment of Parkinson's disease with aporphines. Possible role of growth hormone. N Engl J Med. 1976 Mar 11;294(11):567–572. doi: 10.1056/NEJM197603112941101. [DOI] [PubMed] [Google Scholar]
- Del Pozo E., Del Re R. B., Varga L., Friesen H. The inhibition of prolactin secretion in man by CB-154 (2-Br-alpha-ergocryptine). J Clin Endocrinol Metab. 1972 Nov;35(5):768–771. doi: 10.1210/jcem-35-5-768. [DOI] [PubMed] [Google Scholar]
- Lal S., De la Vega C. E., Sourkes T. L., Friesen H. G. Effect of apomorphine on growth hormone, prolactin, luteinizing hormone and follicle-stimulating hormone levels in human serum. J Clin Endocrinol Metab. 1973 Nov;37(5):719–724. doi: 10.1210/jcem-37-5-719. [DOI] [PubMed] [Google Scholar]
- Lieberman A., Miyamoto T., Battista A. F., Goldstein M. Studies on the antiparkinsonism efficacy of lergotrile. Neurology. 1975 May;25(5):459–462. doi: 10.1212/wnl.25.5.459. [DOI] [PubMed] [Google Scholar]
- Mena I., Cotzias G. C. Protein intake and treatment of Parkinson's disease with levodopa. N Engl J Med. 1975 Jan 23;292(4):181–184. doi: 10.1056/NEJM197501232920404. [DOI] [PubMed] [Google Scholar]
- Shoulson I., Glaubiger G. A., Chase T. N. On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology. 1975 Dec;25(12):1144–1148. doi: 10.1212/wnl.25.12.1144. [DOI] [PubMed] [Google Scholar]
- Sweet R. D., McDowell F. H. Plasma dopa concentrations and the "on-off" effect after chronic treatment of Parkinson's disease. Neurology. 1974 Oct;24(10):953–956. doi: 10.1212/wnl.24.10.953. [DOI] [PubMed] [Google Scholar]
- Tolosa E. S., Martin W. E., Cohen H. P., Jacobson R. L. Patterns of clinical response and plasma dopa levels in Parkinson's disease. Neurology. 1975 Feb;25(2):177–183. doi: 10.1212/wnl.25.2.177. [DOI] [PubMed] [Google Scholar]